Driving CAR T Cells against Solid Tumors.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
06 07 2022
Historique:
pubmed: 30 4 2022
medline: 8 7 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

During the American Association for Cancer Research Annual Meeting 2022, researchers discussed ways to improve chimeric antigen receptor T-cell therapy's efficacy in solid tumors. These included sussing out differences between solid and blood cancers in their susceptibility to CAR T cells' cytotoxicity, taking a modular approach to engineering next-generation agents, and building in breaks for exhaustion-prone CAR T cells to restore their function.

Identifiants

pubmed: 35485880
pii: 694819
doi: 10.1158/2159-8290.CD-ND2022-0006
doi:

Substances chimiques

Receptors, Antigen, T-Cell 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

OF4

Informations de copyright

©2022 American Association for Cancer Research.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH